MA34646B1 - Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17 - Google Patents

Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17

Info

Publication number
MA34646B1
MA34646B1 MA35872A MA35872A MA34646B1 MA 34646 B1 MA34646 B1 MA 34646B1 MA 35872 A MA35872 A MA 35872A MA 35872 A MA35872 A MA 35872A MA 34646 B1 MA34646 B1 MA 34646B1
Authority
MA
Morocco
Prior art keywords
antagonists
methods
treating psoriasis
antibody
binding molecule
Prior art date
Application number
MA35872A
Other languages
English (en)
French (fr)
Inventor
Achim Guettner
Matthias Machacek
Charis Papavassilis
Oliver Sander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34646(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34646B1 publication Critical patent/MA34646B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA35872A 2010-10-08 2013-05-03 Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17 MA34646B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Publications (1)

Publication Number Publication Date
MA34646B1 true MA34646B1 (fr) 2013-11-02

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35872A MA34646B1 (fr) 2010-10-08 2013-05-03 Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17

Country Status (28)

Country Link
US (9) US9717791B2 (cg-RX-API-DMAC7.html)
EP (5) EP3792281A1 (cg-RX-API-DMAC7.html)
JP (2) JP5537740B2 (cg-RX-API-DMAC7.html)
KR (3) KR101620771B1 (cg-RX-API-DMAC7.html)
CN (2) CN107029234A (cg-RX-API-DMAC7.html)
AU (1) AU2011311482B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013008501A2 (cg-RX-API-DMAC7.html)
CA (1) CA2813900C (cg-RX-API-DMAC7.html)
CL (1) CL2013000930A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119942T1 (cg-RX-API-DMAC7.html)
DK (1) DK2625199T3 (cg-RX-API-DMAC7.html)
ES (1) ES2660770T3 (cg-RX-API-DMAC7.html)
HK (1) HK1247932A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20180301T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038334T2 (cg-RX-API-DMAC7.html)
IL (1) IL225310A (cg-RX-API-DMAC7.html)
LT (1) LT2625199T (cg-RX-API-DMAC7.html)
MA (1) MA34646B1 (cg-RX-API-DMAC7.html)
MX (1) MX356279B (cg-RX-API-DMAC7.html)
NO (1) NO2625199T3 (cg-RX-API-DMAC7.html)
PH (1) PH12013500660B1 (cg-RX-API-DMAC7.html)
PL (1) PL2625199T3 (cg-RX-API-DMAC7.html)
PT (1) PT2625199T (cg-RX-API-DMAC7.html)
RU (2) RU2591083C2 (cg-RX-API-DMAC7.html)
SG (1) SG188979A1 (cg-RX-API-DMAC7.html)
SI (1) SI2625199T1 (cg-RX-API-DMAC7.html)
TW (2) TWI548419B (cg-RX-API-DMAC7.html)
WO (1) WO2012045848A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
CN104800844A (zh) 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US20150064193A1 (en) * 2011-11-21 2015-03-05 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
WO2014143540A1 (en) * 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
SG10201804954UA (en) * 2013-03-15 2018-07-30 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
EP3033107A1 (en) * 2013-08-15 2016-06-22 Novartis AG Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
MY184189A (en) * 2014-03-31 2021-03-24 Amgen K A Inc Methods of treating nail and scalp psoriasis
CA3198322A1 (en) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
SG11201701276SA (en) * 2014-08-26 2017-03-30 Kirin Amgen Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
DK3191120T3 (da) 2014-09-10 2024-07-15 Novartis Ag Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
ES3000557T3 (en) 2015-03-02 2025-02-28 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
RU2754683C2 (ru) 2015-10-27 2021-09-06 Юсб Биофарма Срл Способы лечения с использованием анти-il-17a антител
EP4477265A3 (en) 2016-07-19 2025-03-19 Novartis AG Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
WO2019040230A1 (en) * 2017-08-23 2019-02-28 Eli Lilly And Company TREATMENT OF GENITAL PSORIASIS
TWI725532B (zh) * 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
CN114127108A (zh) 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
KR20220066318A (ko) 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
RS51142B (sr) * 2005-09-01 2010-10-31 Schering Corporation Primena antagonista il-23 i il-17 za lečenje autoimunog okularnog zapaljenskog oboljenja
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
RU2341272C1 (ru) 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
WO2010034443A1 (en) * 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof

Also Published As

Publication number Publication date
WO2012045848A1 (en) 2012-04-12
CA2813900C (en) 2017-01-10
US20230321231A1 (en) 2023-10-12
US20200171147A1 (en) 2020-06-04
DK2625199T3 (en) 2018-02-26
PH12013500660B1 (en) 2017-10-27
US20250161443A1 (en) 2025-05-22
CN107029234A (zh) 2017-08-11
KR20150018595A (ko) 2015-02-23
US10583190B2 (en) 2020-03-10
IL225310A (en) 2016-10-31
HK1247932A1 (en) 2018-10-05
US20130202610A1 (en) 2013-08-08
JP2013543501A (ja) 2013-12-05
NO2625199T3 (cg-RX-API-DMAC7.html) 2018-04-21
US20170304439A1 (en) 2017-10-26
HRP20180301T1 (hr) 2018-03-23
CA2813900A1 (en) 2012-04-12
US20250161444A1 (en) 2025-05-22
US20250161445A1 (en) 2025-05-22
TWI548419B (zh) 2016-09-11
EP2625199B1 (en) 2017-11-22
CL2013000930A1 (es) 2014-03-28
BR112013008501A2 (pt) 2016-08-16
EP2625199A1 (en) 2013-08-14
ES2660770T3 (es) 2018-03-26
CN103154031A (zh) 2013-06-12
RU2591083C2 (ru) 2016-07-10
TWI564022B (zh) 2017-01-01
JP5537740B2 (ja) 2014-07-02
KR20130110179A (ko) 2013-10-08
KR101620771B1 (ko) 2016-05-12
PH12013500660A1 (en) 2013-05-20
HUE038334T2 (hu) 2018-10-29
US20210162044A1 (en) 2021-06-03
CY1119942T1 (el) 2018-12-12
MX2013003916A (es) 2013-06-03
JP2014114288A (ja) 2014-06-26
SG188979A1 (en) 2013-05-31
TW201216984A (en) 2012-05-01
AU2011311482B2 (en) 2014-05-29
US20210113688A1 (en) 2021-04-22
US11534490B2 (en) 2022-12-27
SI2625199T1 (en) 2018-03-30
PL2625199T3 (pl) 2018-04-30
EP3299390A1 (en) 2018-03-28
EP4137514A1 (en) 2023-02-22
EP4670788A2 (en) 2025-12-31
RU2665954C1 (ru) 2018-09-05
IL225310A0 (en) 2013-06-27
PT2625199T (pt) 2018-02-28
US9717791B2 (en) 2017-08-01
AU2011311482A1 (en) 2013-04-04
RU2013120957A (ru) 2014-11-20
MX356279B (es) 2018-05-22
EP3792281A1 (en) 2021-03-17
LT2625199T (lt) 2018-03-12
KR20140097566A (ko) 2014-08-06
TW201630625A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
MA34646B1 (fr) Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17
MA34647B1 (fr) Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
EA201290515A1 (ru) Аминопиримидины в качестве syk ингибиторов
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
MA29330B1 (fr) Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires.
ATE464305T1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
EP1861399A4 (en) CGRP RECEPTOR ANTAGONISTS
EP1606286A4 (en) BENZODIAZEPINE SPIROHYDANTOINES AS CGRP RECEPTOR ANTAGONISTS
MA35404B1 (fr) Composés pour le traitement de la toxicomanie
MA38161A1 (fr) Anticorps anti-bmp-6
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
MA47221A1 (fr) Anticorps monoclonal à pd-l1
FR2942798B1 (fr) Peptides utilisables pour le traitement de la leucemie lymphoide chronique